<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956615</url>
  </required_header>
  <id_info>
    <org_study_id>UZBRU_MUM</org_study_id>
    <nct_id>NCT03956615</nct_id>
  </id_info>
  <brief_title>sdAb-based TRNT of Multiple Myeloma: a Feasibility Study</brief_title>
  <acronym>MUM</acronym>
  <official_title>sdAb-based Targeted Radionuclide Therapy of Multiple Myeloma: a Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>stichting tegen kanker</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to show that antiidiotypic sdAb are a new, sensitive, specific and
      non-invasive tool for imaging and therapeutic purposes and provides a rationale for their
      clinical evaluation as a personalized treatment option for MM patients expressing surface
      paraprotein.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2031</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2031</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fraction of patients (n=5) for whom a sdAb could be generated that binds to the idiotype of the paraprotein.</measure>
    <time_frame>Within 2 years after study completion</time_frame>
    <description>Reporting of the relative amount of patients for whom such sdAb could be successfully obtained</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of paraprotein-targeting sdAbs generated per patient and amount of sdAb families identified.</measure>
    <time_frame>Within 2 years after study completion</time_frame>
    <description>Absolute amount of unique sdAbs obtained per patient and its average over all patients with successful generation of sdAb</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Affinities of generated paraprotein-targeting sdAbs using BIAcore technology and ELISA techniques.</measure>
    <time_frame>Within 2 years after study completion</time_frame>
    <description>Reporting of affinity (Kd) of selected sdAb per patient measured using BIAcore and ELISA techniques</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>binding capacity to patient-derived myeloma cells (if available)</measure>
    <time_frame>Within 10 years after study completion</time_frame>
    <description>Binding of paraprotein-targeting sdAb to membrane-expressed paraprotein of multiple myeloma cells, obtained as leftover material from routinely performed bone marrow sampling in the 10 years after inclusion of the study subject, measured by mean fluorescence intensity in flow cytometry and/or semiquantitative scoring after immunohistochemistry staining of samples</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling and bone marrow analysis</intervention_name>
    <description>Bone marrow sample analysis. A blood sampling of maximally 10 ml by venous puncture (serum)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients will only be included in the study if they meet all of the following criteria:

          -  Patients who have given informed consent

          -  Patients at least 18 years old

          -  Patients scheduled to undergo bone marrow sampling in clinical routine because of a
             clinically suspected or pathologically confirmed multiple myeloma.

        Exclusion Criteria:

        Patients will not be included in the study if one of the following criteria applies:

          -  Patients who cannot communicate reliably with the investigator

          -  Patients who are unlikely to cooperate with the requirements of the study

          -  Patients at increased risk of death from a pre-existing concurrent illness

          -  Patients who participated already in part I of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marleen Keyaerts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UZ Brussel</last_name>
    <phone>+3224776013</phone>
    <email>afspraak_nucleaire@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marleen Keyaerts, MD</last_name>
    <phone>+3224776013</phone>
    <email>afspraak_nucleaire@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marleen Keyaerts, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

